Neoadjuvant therapy for triple negative breast cancer (TNBC) has recently generated growing interest given the
more aggressive biologic characteristics of such subtype and the lack of approved targeted therapies. Systemic
chemotherapy represents the mainstay of treatment for TNBC. Although neoadjuvant chemotherapy has consistently
demonstrated higher response rates for TNBC compared to non-TNBC, and the pathological complete response predicts
long-term outcome, most patient display residual disease with a higher risk of relapse. In order to improve the outcome of TNBC new
chemotherapic combinations, including platinum agents, and different targeted agents such as antiangiogenetics, poly-ADP ribose
polymerase (PARP) inhibitors and other small molecule inhibitors are being evaluated in neoadjuvant setting. Currently, the research is
ongoing to further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and
to individualize the treatment. In this regard, the neoadjuvant setting may represent the best potential scenario to assess the activity and
the sensitivity of novel agents.
Keywords: Breast cancer, chemotherapy, neoadjuvant, targeted therapy, triple negative.
Rights & PermissionsPrintExport